• INTEGRA - Productive pipetting from 1 to 384 channels
  • We make diagnostics that matter
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • Subscribe, it’s free!
  • Search
  • Menu Menu
Clinical Laboratory int.

Archive for category: E-News

E-News

BARDA issues $19M contract to Hologic to support IVD approval of COVID assays

, 25 January 2023/in E-News /by panglobal

Hologic has been awarded a US$19 million contract from the U.S.-based Biomedical Advanced Research and Development Authority (BARDA) to support research and development efforts for its Panther Fusion SARS-CoV-2/Flu A/B/RSV assay and Aptima SARS-CoV-2 assay.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/01/hologic_logo.png 559 1728 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-01-25 10:34:362023-01-25 10:34:36BARDA issues $19M contract to Hologic to support IVD approval of COVID assays

Researchers scale production of designer immune cells for drug discovery

, 25 January 2023/in E-News /by panglobal

To prevent testing on animals and create even more precise ways of testing therapeutics, the pharmaceutical industry is increasingly turning to human immune cells. However, the availability of cells like these has been limited to date. Now, Fraunhofer researchers have succeeded in scaling the production of customized immune cells from laboratory up to industrial level.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/01/Prof_Lachmann.png 1254 941 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-01-25 10:32:382023-01-25 10:32:38Researchers scale production of designer immune cells for drug discovery

Fujifilm enters into asset purchase agreement to acquire Inspirata’s digital pathology business

, 25 January 2023/in E-News /by panglobal

FUJIFILM Corporation has entered into an asset purchase agreement to acquire the global digital pathology business Inspirata, based in Tampa, Florida. Upon completion of this agreement, Inspirata’s Dynamyx digital pathology technology, employees and customers will become part of Fujifilm. The addition of digital pathology will expand Fujifilm’s robust Synapse Enterprise Imaging offering to enable the […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/01/fujifilm-scaled.jpg 1440 2560 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-01-25 10:27:292023-01-25 10:27:29Fujifilm enters into asset purchase agreement to acquire Inspirata’s digital pathology business

Inivos Scientific rebrands to VITTA Group

, 25 January 2023/in E-News /by panglobal

Inivos Scientific, the parent company behind Edulab and Science & Chemical Supplies (SciChem), has rebranded and restructured the business to reflect its evolution and strategic growth plans.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/01/VITTA-GROUP_logo.jpg 464 572 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-01-25 10:23:482023-01-25 10:25:35Inivos Scientific rebrands to VITTA Group

EpiEndo commences Phase 2a Trial for EP395 in COPD patients

, 25 January 2023/in E-News /by panglobal

EpiEndo Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapeutics for chronic inflammatory diseases, has received regulatory approval to commence a Phase 2a clinical trial with lead molecule EP395 in COPD (Chronic Obstructive Pulmonary Disease) patients. EP395 is an orally available macrolide or ‘Barriolide’, with reduced antimicrobial resistance potential, which aims to address the unmet medical need […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/01/shutterstock_2029745360-scaled.jpg 1707 2560 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-01-25 10:21:142023-01-25 10:21:14EpiEndo commences Phase 2a Trial for EP395 in COPD patients

Coriolis Pharma appoints formulation and drug development expert Bruce Kerwin to Scientific Advisory Board

, 25 January 2023/in E-News /by panglobal

Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of pharmaceutical drugs, including cell and gene therapy products and vaccines, is strengthening its scientific advisory board with the appointment of Bruce Kerwin.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/01/Coriolis_-Bruce_Kerwin.png 675 1200 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-01-25 10:19:262023-01-25 10:35:24Coriolis Pharma appoints formulation and drug development expert Bruce Kerwin to Scientific Advisory Board

Bioventure, Minapharm Pharmaceuticals and MiGenTra sign exclusive agreement for commercialization of multiple biosimilar candidates of Alvotech in the MENA

, 25 January 2023/in E-News /by panglobal

Bioventure, a Dubai-based pharmaceutical company, Minapharm Pharmaceuticals, a Cairo-based pharmaceutical company, and MiGenTra, a Berlin-based pharmaceutical company, have signed an exclusive license agreement for the commercialization of multiple biosimilar candidates developed and manufactured by Alvotech, in Egypt and eighteen additional countries in Africa and the Middle East.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/01/shutterstock_1110645284-scaled.jpg 1294 2560 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-01-25 10:17:182023-01-25 10:17:31Bioventure, Minapharm Pharmaceuticals and MiGenTra sign exclusive agreement for commercialization of multiple biosimilar candidates of Alvotech in the MENA

CardiNor enter into a distribution agreement with Demeditec Diagnostics GmbH for the CE marked CardiNor Secretoneurin ELISA test

, 25 January 2023/in E-News /by panglobal

Cardiovascular DX company CardiNor AS today announces that it has signed an exclusive agreement with Demeditec for sales of the CE marked CardiNor Secretoneurin ELISA test in Germany. In addition, the agreement gives Demeditec the right to sell the test, on non-exclusive basis, in 15 countries outside Europe which includes India, South Korea, Mexico and […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/01/CardiNor-Produkt_Web_02-1-scaled.jpg 1708 2560 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-01-25 10:07:572023-01-25 10:14:25CardiNor enter into a distribution agreement with Demeditec Diagnostics GmbH for the CE marked CardiNor Secretoneurin ELISA test

Agilent opens Customer Experience Center highlighting genomics and diagnostics solutions

, 25 January 2023/in E-News /by panglobal

Agilent Technologies has opened a new Customer Experience Center (CEC) in Lexington, Massachusetts, U.S., focused on solutions from Agilent genomics and diagnostics product portfolios. The facility will serve as a regional hub for Agilent representatives to showcase and demonstrate both product capabilities and complete workflow solutions to customers.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/01/agilent-new-centre-scaled.jpg 1920 2560 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-01-25 10:02:492023-01-25 10:02:49Agilent opens Customer Experience Center highlighting genomics and diagnostics solutions

Ubiquigent collaborates with University of Glasgow on translational structural biology to accelerate drug discovery within the (de)ubiquitylation field

, 23 January 2023/in E-News /by panglobal

Supporting Master’s student in Prof Helen Walden’s laboratory Project aims to determine USP30 structure to inform the design and discovery of novel inhibitors

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/01/image005.png 75 342 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-01-23 12:28:472023-01-23 12:30:46Ubiquigent collaborates with University of Glasgow on translational structural biology to accelerate drug discovery within the (de)ubiquitylation field
Page 2 of 184‹1234›»
We make diagnostics that matter

Latest issue of Clinical laboratory

December 2022 / January 2023

27 January 2023

DiaSys Procalcitonin FS is a fluid-stable, particle enhanced immunoturbidimetric assay, applicable on various clinical chemistry analyzers.

26 January 2023

Tetra Pharm Technologies secures €9 million in Series A Round to expand R&D Operations

26 January 2023

Watchmaker Genomics is proud to announce that its Quality Management System has achieved ISO 13485:2016 certification.

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

Sign up today
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release

Hastelweg 250
5652 CN Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only